T. Rowe Price Investment Management’s Avalo Therapeutics AVTX Stock Holding History

T. Rowe Price Investment Management’s Portfolio AVTX Stock Details AVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$32.3M	Buy	+2,162,684	New	+$33.8M	0.02%	409

Other funds holding AVTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

T. Rowe Price Investment Management's AVTX Position: Q1 2026 in Review

T. Rowe Price Investment Management opened a new position in Avalo Therapeutics (AVTX) in Q1 2026: 2,162,684 shares worth $32.3M. The stake represents 0.02% of the portfolio and ranks #409 among its holdings.

97 funds tracked by Wall St. Rank hold AVTX as of Q1 2026.

T. Rowe Price Investment Management held 2,162,684 shares of Avalo Therapeutics worth $32.3M as of Q1 2026.
Avalo Therapeutics was a new T. Rowe Price Investment Management position in Q1 2026.
Avalo Therapeutics made up 0.02% of T. Rowe Price Investment Management's portfolio in Q1 2026, its #409 holding.
97 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q1 2026, filed 15 May 2026.